The study links a common class of antidepressants and a genetic variant with faster progression of degenerative mitral regurgitation in some patients. That combination highlights how medicines and inherited differences can interact in unexpected ways. For people managing mood disorders while also living with valve disease, such interactions could affect timing of follow-up, imaging, or surgical planning.
This work raises practical questions that touch on human potential and inclusion in care. Which patients should be tested for the genetic variant? How can clinicians balance mental health treatment with heart health? Exploring those answers could help more people stay active and productive for longer. Follow the link to see the data and consider how this research might reshape personalized care for diverse patients.
Scientists have uncovered evidence that serotonin, the chemical best known for regulating mood, may also speed the progression of a common heart valve disease in some people. The research suggests that patients with degenerative mitral regurgitation who take SSRI antidepressants and carry a specific genetic variant may develop severe valve damage sooner, potentially requiring surgery at a younger age.
